... Lonza’s expansion … Investing in Future Growth in Lonza Pharma Biotech & Nutrition (LPBN) LPBN continues its accelerated growth trajectory, with an expanding portfolio of customers and offerings. Today we are one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Funk had also focused on growing Lonza’s pharmaceuticals, biotech and nutrition business, including a $415 million expansion of drug manufacturing facilities in Visp…
The new facility will support the long-term manufacturing agreement Lonza recently made with AstraZeneca to deliver a number of products from across the pharma giant's portfolio. Visp remains our largest site and one of the most significant for R&D, development and manufacturing. Lonza said its manufacturing site in Visp, Switzerland, was for the third time approved for production of a new antibody-drug-conjugate (ADC) for a client. Lonza Group Ltd│ Muenchensteinerstrasse 38 │H-4002 asel │Switzerland +41 61 316 81 11 │ www.lonza.com │ media@lonza.com Basel, Switzerland, 24 July 2019 – Lonza today announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of The Swiss CDMO says it intends to name a new leader … Lonza, the Swiss Contract Development and Manufacturing Organization (CDMO), has confirmed the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug conjugate (ADC) produced at the site.. Manufacturing of ADCs under cGMP presents unique challenges. Lonza has completed a US$15 million multi-phase expansion of its solid oral dose development and manufacturing capabilities and capacity. During that restructuring, Lonza terminated 200 positions at its microbial biologics plant in Hopkinton, Mass., as part of a consolidation of multiple facilities into one at the company’s Visp, Switzerland facility. The facility "will provide current and future customers with launch and commercial manufacturing and will serve the rapidly expanding early clinical phase market for bioconjugates," the company said. The Visp biopark in the Swiss Alps is Lonza’s main location and is housing most of the companies manufacturing research and development operations. Visp in Switzerland is the founding location of Lonza Group. The site will be completed by 2020 and will hold all elements of antibody-drug conjugate (ADC) production in a single site.
The expansion will take two years, and contracts are already in place for the extra capacity, according to Lonza. One of the challenges is that … The Visp site Lonza has announced an investment in a major expansion of HPAPI manufacturing capacity at its Visp, Switzerland site.
Lonza announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the site. Lonza is developing a new biomanufacturing complex at its biopark in Visp, Switzerland.
Copyright 2020 lonza visp expansion